000			nab a22 7a 4500
999			_c16895 _d16895
003			PC16895
005			20220603134724.0
008			220603b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9389 _aMartínez López, Joaquín _eHematología y Hemoterapia
100			_93057 _aLópez Anglada, Lucía _eHematología y Hemoterapia
100			_9390 _aCedena Romero, María Teresa _eHematología
100			_93058 _aSáez Gómez, María Auxiliadora _eHematología y Hemoterapia
100			_91468 _aRapado Martínez, Inmaculada _eInstituto de Investigación i+12
100			_93059 _aCueto Felgueroso, Cecilia _eHematología y Hemoterapia
100			_9388 _aLahuerta Palacios, Juan José _eHematología y Hemoterapia
245	0	0	_aCritical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. _h[artículo]
260			_bBlood, _c2015
300			_a126(7):858-62.
500			_aFormato Vancouver: Martínez López J, Paiva B, López Anglada L, Mateos MV, Cedena T, Vidríales MB et al; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood. 2015 Aug 13;126(7):858-62.
501			_aPMID: 26089396 PMC4543912
504			_aContiene 21 referencias
520			_aStringent complete response (sCR) criteria are used in multiple myeloma as a deeper response category compared with CR, but prospective validation is lacking, it is not always clear how evaluation of clonality is performed, and is it not known what the relative clinical influence is of the serum free light chain ratio (sFLCr) and bone marrow (BM) clonality to define more sCR. To clarify this controversy, we focused on 94 patients that reached CR, of which 69 (73%) also fulfilled the sCR criteria. Patients with sCR displayed slightly longer time to progression (median, 62 vs 53 months, respectively; P = .31). On analyzing this contribution to the prognosis of sFLCr or clonality, it was found that the sFLCr does not identify patients in CR at distinct risk; by contrast, low-sensitive multiparametric flow cytometry (MFC) immunophenotyping (2 colors), which is equivalent to immunohistochemistry, identifies a small number of patients (5 cases) with high residual tumor burden and dismal outcome; nevertheless, using traditional 4-color MFC, persistent clonal BM disease was detectable in 36% of patients, who, compared with minimal residual disease-negative cases, had a significantly inferior outcome. These results show that the current definition of sCR should be revised.
710			_9297 _aServicio de Hematología y Hemoterapia
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16895.pdf _ySolicitar documento
942			_2ddc _cART _n0